The prognostic value of TP53 and tumor suppressor gene mutations in temozolomide-treated IDH1 mutant low-grade glioma

被引：0
|
作者：
Salem, Yahia E.
Abu Alragheb, Bayan O.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7361
引用
收藏
页数：2
相关论文
共 46 条
  • [1] Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
    Bendahou, Mohammed Amine
    Arrouchi, Housna
    Lakhlili, Wiame
    Allam, Loubna
    Aanniz, Tarik
    Cherradi, Nadia
    Ibrahimi, Azeddine
    Boutarbouch, Mahjouba
    CANCER INFORMATICS, 2020, 19
  • [2] MUTATIONS IN IDH1 AND TP53 AS PROGNOSTIC BIOMARKERS IN BULGARIAN PATIENTS WITH GLIOMAS
    Goranova, T.
    Stancheva, G.
    Mitkova, A.
    Kaneva, R.
    Poptodorov, G.
    Velinov, N.
    Mitev, V.
    Gabrovsky, N.
    NEURO-ONCOLOGY, 2010, 12 : 33 - 33
  • [3] IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    Dubbink, H. J.
    Taal, W.
    van Marion, R.
    Kros, J. M.
    van Heuvel, I.
    Bromberg, J. E.
    Zonnenberg, B. A.
    Zonnenberg, C. B. L.
    Postma, T. J.
    Gijtenbeek, J. M. M.
    Boogerd, W.
    Groenendijk, F. H.
    Smitt, P. A. E. Sillevis
    Dinjens, W. N. M.
    van den Bent, M. J.
    NEUROLOGY, 2009, 73 (21) : 1792 - 1795
  • [4] TEXTILOMA RESEMBLING ANAPLASTIC PROGRESSION OF AN IDH1 MUTANT, LOW-GRADE GLIOMA
    Anderson, Mark D.
    Raghunathan, Aditya
    Aldape, Kenneth D.
    Fuller, Greg N.
    Gilbert, Mark R.
    NEURO-ONCOLOGY, 2012, 14 : 67 - 67
  • [5] IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    Houillier, C.
    Wang, X.
    Kaloshi, G.
    Mokhtari, K.
    Guillevin, R.
    Laffaire, J.
    Paris, S.
    Boisselier, B.
    Idbaih, A.
    Laigle-Donadey, F.
    Hoang-Xuan, K.
    Sanson, M.
    Delattre, J. -Y.
    NEUROLOGY, 2010, 75 (17) : 1560 - 1566
  • [6] The prognostic significance of 1p/19q-Deletionen, MGMT Methylation, TP53 and IDH1/2-Mutations for Patients with no adjuvant-treated low-grade Gliomas.
    Hartmann, C.
    Hentschel, B.
    Tonn, J.
    Schramm, J.
    Westphal, M.
    Loeffler, M.
    Weller, M.
    ONKOLOGIE, 2010, 33 : 54 - 54
  • [7] THE PROGNOSTIC/PREDICTIVE ROLE OF IDH1 GENE MUTATIONS IN PATIENTS TREATED FOR RECURRENT GLIOMA
    Lv, S.
    Sadones, J.
    Teugels, E.
    Huylebrouck, M.
    De Witte, O.
    Salmon, I.
    Michotte, A.
    De Greve, J.
    Neyns, B.
    NEURO-ONCOLOGY, 2010, 12 : 31 - 32
  • [8] Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation
    Wang, Kai
    Wang, Yin-Yan
    Ma, Jun
    Wang, Jiang-Fei
    Li, Shao-Wu
    Jiang, Tao
    Dai, Jian-Ping
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (24) : 10893 - 10898
  • [9] Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine
    Bally, Cecile
    Ades, Lionel
    Renneville, Aline
    Preudhomme, Claude
    Mozziconacci, Marie-Joelle
    de The, Hugues
    Lehmann-Che, Jacqueline
    Fenaux, Pierre
    BLOOD, 2012, 120 (21)
  • [10] Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma
    Sfifou, Fatima
    Ouzir, Mounir
    Hakkou, El Mehdi
    Obtel, Majdouline
    Errihani, Hassan
    Al Bouzidi, Abderrahmane
    Abouqal, Redouane
    El Ouahabi, Abdessamad
    Cherradi, Nadia
    JOURNAL OF CHEMICAL NEUROANATOMY, 2022, 119
12345